See more : Nanologica AB (publ) (NICA.ST) Income Statement Analysis – Financial Results
Complete financial analysis of ThermoGenesis Holdings, Inc. (THMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ThermoGenesis Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Imricor Medical Systems, Inc. (IMR.AX) Income Statement Analysis – Financial Results
- Oakajee Corporation Limited (OKJ.AX) Income Statement Analysis – Financial Results
- Shaanxi Beiyuan Chemical Industry Group Co., Ltd. (601568.SS) Income Statement Analysis – Financial Results
- Paisalo Digital Limited (PAISALO.NS) Income Statement Analysis – Financial Results
- T2 Metals Corp. (AGLAF) Income Statement Analysis – Financial Results
ThermoGenesis Holdings, Inc. (THMO)
About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.45M | 10.48M | 9.29M | 9.74M | 13.05M | 9.67M | 12.03M | 14.53M | 11.93M | 16.04M | 15.99M | 17.96M | 19.02M | 23.40M | 23.09M | 19.80M | 21.95M | 16.75M | 12.05M | 10.18M | 11.65M | 10.19M | 9.55M | 5.79M | 4.21M | 5.10M | 4.50M | 6.60M | 4.10M | 3.30M | 2.70M | 2.00M | 1.80M | 1.80M | 1.10M | 1.20M | 500.00K | 100.00K |
| Cost of Revenue | 7.51M | 7.77M | 5.80M | 8.49M | 7.35M | 7.48M | 7.72M | 8.69M | 9.19M | 11.29M | 10.10M | 11.60M | 12.69M | 14.56M | 15.64M | 14.11M | 14.98M | 11.55M | 7.71M | 7.09M | 7.84M | 7.90M | 7.56M | 5.01M | 4.25M | 3.70M | 5.00M | 4.00M | 1.60M | 1.90M | 1.40M | 1.00M | 1.20M | 600.00K | 400.00K | 500.00K | 100.00K | 0.00 |
| Gross Profit | 1.93M | 2.71M | 3.49M | 1.26M | 5.70M | 2.19M | 4.31M | 5.84M | 2.74M | 4.75M | 5.89M | 6.37M | 6.33M | 8.84M | 7.45M | 5.69M | 6.97M | 5.20M | 4.34M | 3.09M | 3.80M | 2.29M | 1.99M | 780.00K | -35.00K | 1.40M | -500.00K | 2.60M | 2.50M | 1.40M | 1.30M | 1.00M | 600.00K | 1.20M | 700.00K | 700.00K | 400.00K | 100.00K |
| Gross Profit Ratio | 20.44% | 25.85% | 37.58% | 12.92% | 43.66% | 22.67% | 35.84% | 40.20% | 23.00% | 29.60% | 36.82% | 35.43% | 33.29% | 37.76% | 32.25% | 28.75% | 31.76% | 31.03% | 36.05% | 30.34% | 32.65% | 22.45% | 20.85% | 13.47% | -0.83% | 27.45% | -11.11% | 39.39% | 60.98% | 42.42% | 48.15% | 50.00% | 33.33% | 66.67% | 63.64% | 58.33% | 80.00% | 100.00% |
| Research & Development | 1.28M | 1.66M | 2.21M | 2.48M | 2.40M | 3.01M | 4.49M | 2.50M | 3.23M | 5.94M | 3.47M | 2.99M | 3.73M | 3.00M | 5.01M | 5.22M | 7.17M | 4.11M | 4.16M | 5.67M | 3.47M | 2.94M | 2.28M | 1.78M | 1.62M | 2.00M | 3.90M | 3.60M | 1.30M | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 5.73M | 6.38M | 8.29M | 7.92M | 10.87M | 8.23M | 10.70M | 8.49M | 5.65M | 5.22M | 5.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 1.95M | 1.66M | 1.36M | 1.69M | 1.53M | 2.15M | 2.97M | 2.97M | 2.96M | 2.76M | 3.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.22M | 7.24M | 8.52M | 7.68M | 8.03M | 9.65M | 9.01M | 12.40M | 10.38M | 13.67M | 11.46M | 8.60M | 7.98M | 8.67M | 7.69M | 9.25M | 10.17M | 9.63M | 7.16M | 5.84M | 5.17M | 5.01M | 4.84M | 3.89M | 4.20M | 4.80M | 4.60M | 3.50M | 1.60M | 1.10M | 1.80M | 1.30M | 1.90M | 1.30M | 1.10M | 1.00M | 1.30M | 600.00K |
| Other Expenses | 0.00 | -3.00K | 802.00K | -8.00K | -33.00K | -24.00K | 0.00 | 180.00K | -44.00K | 21.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.54M | 8.90M | 10.72M | 10.15M | 10.43M | 12.66M | 13.51M | 14.90M | 13.61M | 19.61M | 14.93M | 11.59M | 11.71M | 11.67M | 12.70M | 14.47M | 17.34M | 13.74M | 11.31M | 11.51M | 8.65M | 7.95M | 7.13M | 5.67M | 5.82M | 7.40M | 9.00M | 7.40M | 3.10M | 1.70M | 1.90M | 1.50M | 2.10M | 1.60M | 1.30M | 1.10M | 1.40M | 700.00K |
| Cost & Expenses | 18.33M | 16.68M | 16.53M | 18.64M | 17.78M | 20.14M | 21.22M | 23.58M | 22.79M | 30.90M | 25.03M | 23.19M | 24.40M | 26.24M | 28.34M | 28.58M | 32.31M | 25.29M | 19.02M | 18.60M | 16.49M | 15.85M | 14.68M | 10.68M | 10.07M | 11.10M | 14.00M | 11.40M | 4.70M | 3.60M | 3.30M | 2.50M | 3.30M | 2.20M | 1.70M | 1.60M | 1.50M | 700.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.19M | 1.77M | 828.00K | 216.00K | 90.00K | 0.00 | 110.00K | 130.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 10.03M | 5.62M | 6.10M | 7.91M | 4.48M | 2.70M | 0.00 | 20.52M | 7.99M | 14.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00K | 23.00K | 0.00 | 13.00K | 1.11M | 0.00 | 0.00 | 0.00 | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 100.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.15M | 926.00K | 633.00K | 754.00K | 806.00K | 670.00K | 644.00K | 830.00K | 1.17M | 1.35M | 993.00K | 538.00K | 604.00K | 466.00K | 492.00K | 474.00K | 543.00K | 549.00K | 118.00K | 367.00K | 302.00K | 266.00K | 434.00K | 485.00K | 677.00K | 600.00K | 500.00K | 300.00K | 200.00K | 200.00K | 100.00K | 200.00K | 200.00K | 300.00K | 200.00K | 100.00K | 100.00K | 100.00K |
| EBITDA | -7.74M | -5.27M | -6.60M | -8.16M | -4.73M | -42.30M | -8.55M | -8.42M | -9.70M | -13.49M | -8.05M | -4.69M | -4.78M | -2.37M | -4.76M | -8.30M | -9.82M | -7.99M | -6.85M | -8.06M | -4.54M | -5.40M | -4.70M | -4.41M | -5.18M | -5.40M | -9.00M | -4.50M | -400.00K | -100.00K | -500.00K | -300.00K | -1.30M | -100.00K | -400.00K | -300.00K | -900.00K | -500.00K |
| EBITDA Ratio | -81.95% | -50.27% | -62.36% | -83.75% | -30.47% | -101.51% | -71.11% | -55.41% | -81.66% | -84.07% | -50.33% | -38.13% | -25.10% | -10.12% | -20.63% | -41.94% | -44.76% | -47.71% | -56.87% | -79.15% | -39.00% | -52.99% | -49.23% | -76.07% | -122.94% | -105.88% | -200.00% | -68.18% | -9.76% | -12.12% | -18.52% | -15.00% | -72.22% | -5.56% | -36.36% | -33.33% | -200.00% | -600.00% |
| Operating Income | -8.61M | -6.19M | -7.23M | -8.90M | -4.73M | -43.55M | -9.20M | -9.37M | -10.87M | -14.86M | -9.04M | -3.07M | -5.38M | -2.84M | -5.25M | -8.78M | -10.37M | -8.54M | -6.97M | -8.42M | -4.84M | -5.66M | -5.14M | -4.89M | -5.85M | -6.00M | -9.50M | -4.80M | -600.00K | -300.00K | -600.00K | -500.00K | -1.50M | -400.00K | -600.00K | -400.00K | -1.00M | -600.00K |
| Operating Income Ratio | -91.16% | -59.08% | -77.80% | -91.29% | -36.28% | -450.22% | -76.47% | -64.50% | -91.08% | -92.63% | -56.55% | -17.06% | -28.28% | -12.12% | -22.76% | -44.34% | -47.24% | -50.99% | -57.85% | -82.76% | -41.59% | -55.60% | -53.78% | -84.44% | -139.02% | -117.65% | -211.11% | -72.73% | -14.63% | -9.09% | -22.22% | -25.00% | -83.33% | -22.22% | -54.55% | -33.33% | -200.00% | -600.00% |
| Total Other Income/Expenses | -10.31M | -5.62M | -4.65M | -7.92M | -5.37M | -2.13M | -1.00M | -20.53M | -7.72M | 7.00K | 6.00K | -21.00K | 393.00K | 268.00K | 61.00K | 228.00K | 1.19M | 1.77M | 0.00 | 202.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 300.00K | 600.00K | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 100.00K | 100.00K |
| Income Before Tax | -18.92M | -11.81M | -11.88M | -16.81M | -10.10M | -45.67M | -10.02M | -29.77M | -18.59M | -14.85M | -9.03M | -3.09M | -4.99M | -2.57M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -300.00K | -900.00K | -500.00K |
| Income Before Tax Ratio | -200.31% | -112.68% | -127.82% | -172.53% | -77.40% | -472.19% | -83.29% | -204.94% | -155.82% | -92.58% | -56.51% | -17.18% | -26.21% | -10.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -25.00% | -180.00% | -500.00% |
| Income Tax Expense | 0.00 | 5.07M | 6.40M | 7.44M | 3.83M | -4.73M | -4.48M | -673.00K | 7.95M | 35.00K | -403.00K | -2.14M | 0.00 | 0.00 | -61.00K | -228.00K | -1.19M | -1.77M | -828.00K | -202.00K | -67.00K | -61.00K | -97.00K | 1.84M | -36.00K | 100.00K | 100.00K | 0.00 | 0.00 | -200.00K | 0.00 | -200.00K | 0.00 | 300.00K | 200.00K | 100.00K | 100.00K | 200.00K |
| Net Income | -17.98M | -11.27M | -11.38M | -16.35M | -9.50M | -39.72M | -4.57M | -29.10M | -18.59M | -14.85M | -8.63M | -3.09M | -4.99M | -2.57M | -5.19M | -8.55M | -9.18M | -6.78M | -6.14M | -8.22M | -4.78M | -5.60M | -5.04M | -6.73M | -5.82M | -6.10M | -9.60M | -4.80M | -600.00K | -100.00K | 0.00 | -300.00K | -1.50M | -700.00K | -800.00K | -500.00K | -1.10M | -800.00K |
| Net Income Ratio | -190.31% | -107.51% | -122.43% | -167.81% | -72.79% | -410.63% | -37.97% | -200.31% | -155.82% | -92.58% | -53.99% | -17.18% | -26.21% | -10.97% | -22.49% | -43.18% | -41.83% | -40.45% | -50.98% | -80.77% | -41.02% | -55.00% | -52.76% | -116.25% | -138.16% | -119.61% | -213.33% | -72.73% | -14.63% | -3.03% | 0.00% | -15.00% | -83.33% | -38.89% | -72.73% | -41.67% | -220.00% | -800.00% |
| EPS | -7.59 | -20.45 | -43.41 | -117.20 | -151.09 | -971.34 | -203.28 | -1.32K | -2.78K | -3.31K | -3.21K | -1.68K | -2.74K | -1.56K | -3.33K | -5.49K | -5.93K | -4.42K | -4.46K | -6.52K | -4.12K | -5.51K | -5.15K | -7.63K | -8.44K | -10.66K | -18.29K | -10.91K | -1.70K | -283.29 | 0.00 | -1.17K | -6.07K | -3.20K | -4.65K | -3.73K | -8.27K | -6.67K |
| EPS Diluted | -7.59 | -20.45 | -43.41 | -117.20 | -151.09 | -971.34 | -203.28 | -1.32K | -2.78K | -3.31K | -3.21K | -1.68K | -2.74K | -1.56K | -3.33K | -5.49K | -5.93K | -4.42K | -4.46K | -6.52K | -4.12K | -5.51K | -5.15K | -7.63K | -8.44K | -10.66K | -18.29K | -10.91K | -1.70K | -283.29 | 0.00 | -1.17K | -6.07K | -3.20K | -4.65K | -3.73K | -8.27K | -6.67K |
| Weighted Avg Shares Out | 2.37M | 550.99K | 262.13K | 139.51K | 62.86K | 40.89K | 22.46K | 22.04K | 6.69K | 4.48K | 2.69K | 1.84K | 1.82K | 1.65K | 1.56K | 1.56K | 1.55K | 1.53K | 1.38K | 1.26K | 1.16K | 1.02K | 978.00 | 883.00 | 689.00 | 572.00 | 525.00 | 440.00 | 353.00 | 353.00 | 282.00 | 257.00 | 247.00 | 219.00 | 172.00 | 134.00 | 133.00 | 120.00 |
| Weighted Avg Shares Out (Dil) | 2.37M | 550.99K | 262.13K | 139.51K | 62.86K | 40.89K | 22.46K | 22.04K | 6.69K | 4.48K | 2.69K | 1.84K | 1.82K | 1.65K | 1.56K | 1.56K | 1.55K | 1.53K | 1.38K | 1.26K | 1.16K | 1.02K | 978.00 | 883.00 | 689.00 | 572.00 | 525.00 | 440.00 | 353.00 | 353.00 | 282.00 | 257.00 | 247.00 | 219.00 | 172.00 | 134.00 | 133.00 | 120.00 |
Recap: ThermoGenesis Holdings Q2 Earnings
Shares of ThermoGenesis Holdings (NASDAQ:THMO) decreased 2.7% after the company reported Q2 results. Quarterly Results Earnings per share rose 62.75% over the past year to ($0.38), which missed the estimate of ($0.18).
ThermoGenesis Holdings, Inc. (THMO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
ThermoGenesis Holdings, Inc. (THMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ThermoGenesis Holdings to Announce Financial Results for the Second Quarter Ended June 30, 2021 and Provide a Corporate Strategic Update
RANCHO CORDOVA, Calif., Aug. 5, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second...
New Strong Sell Stocks for July 2nd
PDCO, SABR, JRSH, UPWK, and THMO have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2021
3 Penny Stocks on Reddit Making Big Waves Right Now
Which Reddit penny stocks are investors watching right now? Check these 3 out The post 3 Penny Stocks on Reddit Making Big Waves Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q1 2021 Results - Earnings Call Transcript
ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q1 2021 Results - Earnings Call Transcript
Recap: ThermoGenesis Holdings Q1 Earnings
Shares of ThermoGenesis Holdings (NASDAQ:THMO) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 85.59% year over year to ($0.16), which missed the estimate of ($0.13).
3 Short Squeeze Candidates In The Health Care Sector
Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.
ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2021 and Provide a Corporate Strategic Update
RANCHO CORDOVA, Calif., May 6, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter...
ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q4 2020 Results - Earnings Call Transcript
ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q4 2020 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports